4.6 Article

Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

期刊

HEPATOLOGY INTERNATIONAL
卷 11, 期 4, 页码 317-370

出版社

SPRINGER
DOI: 10.1007/s12072-017-9799-9

关键词

Hepatocellular carcinoma; Asia-Pacific; APASL; Treatment algorithm

资金

  1. Bayer
  2. Boehringer Ingelheim
  3. Bristol-Myers Squibb
  4. Otsuka
  5. Astellas
  6. Gilead Sciences
  7. Chugai
  8. Mitsubishi Tanabe
  9. Kyorin
  10. Merck Sharp and Dohme
  11. Dainippon Sumitomo
  12. Vertex Pharmaceuticals
  13. Takeda
  14. Merck Serono
  15. Zeria
  16. Novartis
  17. Eisai
  18. ONXEO
  19. Ono Pharmaceutical
  20. Ajinomoto
  21. AbbVie
  22. Kowa
  23. Taiho
  24. Roche
  25. Grants-in-Aid for Scientific Research [16K10363] Funding Source: KAKEN

向作者/读者索取更多资源

There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia-Pacific region, where HCC is one of the leading public health problems. Since the Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. This latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia-Pacific region, which has a diversity of medical environments.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据